Entering text into the input field will update the search result below

Neuralstem (AMEX: CUR) Q1/11 Results

May 11, 2011 3:04 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Special Situations, Contrarian

Seeking Alpha Analyst Since 2009

Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP - Strategic Planning and Communication at Curis (2001-2002), HQCM focusing on healthcare investments (NYSE:HQH/HQL) from (1985-2001)and founded LifeScience Economics, a healthcare research and analytics firm with offices in Boston, MA and Palo Alto, CA. Past experiences include Thermo Scientific, SWEC following 5 years at the FBI. A former military officer, Henry has been an adjunct professor at Boston University and Golden Gate University where he taught courses in venture capital, corporate finance and strategic development in the universities' graduate business schools.
Q1/11 net loss of $3.1M or $0.07 per share

R&D expanses were $1.73M while G&A logged in at $1.77M with total operating expense of $3.53M. Litigation settlement was $250K. CUR reached a settlement agreement with ReNeuron (LSE: RENE.L) resolving all claims asserted by CUR against RENE.L in Neuralstem v. ReNeuron, Case No#CV 08-02168 R, (AGRx) (in California). RENE.L agreed to immediately compensate CUR, as well as to make future milestone and royalty payments to CUR based on RENE.L’s development of certain products at issue in the case. Gain (loss) from change in fair value adjustment of warrants obligations was $161.8K for a total of non-operating expense was $434.7K. CUR reported Q1/11 net loss of $3.1M, or $0.07 per share, compared with a net loss of $6.8M, or $0.18 per share for Q1/10.   The change from 2010 to 2011 was primarily due to higher non-cash expenses related to warrant accounting for Q1/10compared to Q1/11. For Q1/11, CUR reported an operating loss of $3.53M compared with an operating loss of $3.61M, for the Q1/10. The change from 2010 to 2011 was primarily due to increased research spending relating to clinical trials and increased G&A spending due to rising legal costs. These increases were offset by decreased non-cash stock based compensation expense for Q1/11compared to Q1/10 and collection of a litigation settlement during Q1/11. For Q1/11, cash used in operating activities totaled $2.28M, an increase of $161.4K or 8% compared to Q1/10.   This change was primarily attributed to the cost of starting our small molecule clinical trial. Weighted average common shares outstanding, basis and diluted was 47.69M.

  • Cash, cash equivalents and short-term marketable securities at 3/31/11 was $8.5M.  

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.